By Offering Amplicon and Hybrid Capture on a Single Bioinformatics platform, the Company Expands Capabilities to Cover All Pathogen Sequencing Needs.

WOIPPY, FRANCE, June 8, 2026 /EINPresswire.com/ -- ABL Diagnostics (FR001400AHX6 – “ABLD”), an innovative company specialized in microbiology and pathogen sequencing, today announced the upcoming launch of HybridChek, a new portfolio of proprietary Hybrid Capture-based NGS solutions that marks a major strategic milestone for the company and significantly expands its capabilities in microbial genomics. This launch outlines a permanent innovation effort and strategic milestone, maximizing the company's technological footprint towards pathology and microbiology laboratories globally.

With the introduction of HybridChek, ABL Diagnostics now brings together the two leading targeted sequencing approaches—Amplicon Sequencing and Hybrid Capture Sequencing—within a single, integrated technology portfolio supported by its verified bioinformatics platform DeepChek^® Software and MicrobioChek. This dual capability allows laboratories to select the optimal sequencing strategy for each technical application while maintaining access to the same trusted, high-margin analytical software environment, for genomic characterization, resistance-associated mutation analysis, surveillance, and where applicable, interpretation.

The first HybridChek applications will target HIV and Tuberculosis Whole Genome Sequencing addressing two of the world's most complex infectious diseases:.
- The Tuberculosis Assay: Targets the entire Mycobacterium tuberculosis complex (including M. tuberculosis, M. bovis, M. africanum), achieving up to 99% genome recovery. Its design enables high-resolution genomic analysis of resistance-associated mutations using MicrobioChek software and curated databases, including the WHO catalogue for epidemiological research.

- The HIV Assay: Engineered using a design spanning more than 6,000 HIV-1 Group M genomes to ensure broad coverage of global subtypes and recombinant forms. The solution supports whole-genome analysis, subtype characterization, and mutation profiling within a unified workflow.

HybridChek perfectly complements the legacy DeepChek^® Assay lines. While amplicon sequencing remains highly effective for targeted panels (reverse transcriptase, protease, integrase …), hybrid capture offers immense advantages for whole-genome sequencing, degraded samples, and low-input specimens where PCR-based methods face technical bottlenecks.

Crucially, HybridChek immediately benefits from ABL Diagnostics’ strongest operational differentiator: its verified software ecosystem where some of them are currently CE-IVD marked. HybridChek data can be directly processed through existing DeepChek^® and MicrobioChek platforms—which are already verified across both Amplicon and Hybrid Capture workflows. This prevents multi-vendor software fragmentation inside laboratories, lowers onboarding friction, and drives recurring customer lifetime value. “HybridChek represents much more than a new product line,” said Dr. Sofiane Mohamed, Head of R&D at ABL Diagnostics. “By combining Hybrid Capture and Amplicon technologies with bioinformatics solutions already verified across both approaches, ABL Diagnostics provides laboratories with a uniquely comprehensive answer to today's microbial genomics challenges.”

By delivering both foundational sequencing technologies on its established bioinformatics platform, ABL Diagnostics successfully reinforces its market leadership, positions itself as a comprehensive single-source vendor, and fully addresses the evolving technical demands of partner laboratories worldwide.

This technological expansion positions ABL Diagnostics to expand its capabilities within a growing market sector. According to Grand View Research data (https://www.grandviewresearch.com/horizon/statistics/minimal-residual-disease-testing-market-report/next-generation-sequencing-ngs/hybridization-capture-based-ngs/global), the global Hybridization Capture-based NGS market is estimated at approximately USD 241 million in 2024 and is expected to reach nearly USD 473 million by 2030, driven by the expanding operational requirements of advanced laboratories worldwide. While this global market encompasses various applications, ABL Diagnostics intends to address a targeted portion of this business by focusing purely on its specialized microbiology and pathogen sequencing solutions.

Note: HybridChek products are currently under development and will initially be made available strictly for Research Use Only (RUO). They are not cleared, approved, or intended for use in clinical diagnostic procedures. Clinical utility has not been established.

Forward-Looking Statements Disclaimer (MAR Compliant): This press release contains forward-looking statements involving risks, uncertainties, and market projections from third-party sources. Actual corporate results, regulatory pathways, or development timelines could differ materially from those anticipated due to shifts in global regulation, development variances, or changing competitive dynamics.

About ABL Diagnostics (ABLD)
ABL Diagnostics (ABLD) is an international company that specializes in innovative molecular biology tests and global solutions for its customers:
- Molecular polymerase chain reaction (PCR) detection – UltraGene, and
- Genotyping by DNA sequencing – DeepChek^®.

ABL Diagnostics markets its entire product range globally through its own sales team and a network of exclusive distributors active on all continents. ABL Diagnostics' customers are academic clinical pathology laboratories, private reference laboratories and researchers willing to implement innovative and robust microbiological content in constant expansion.

ABL Diagnostics has been marketing the products and services of its sister company CDL Pharma since the second half of 2025 through an intra-group strategy agreement.

An expanding portfolio of microbiology products:
- HIV – Drug resistance testing, including a whole genome kit.
- SARS-CoV-2, Tuberculosis, Hepatitis B and C – Advanced Detection Solutions.
- Microbiome and taxonomy – 16s/18s RNA-based analyses.
- Other viral and bacterial targets – Comprehensive molecular assays.

Integrated Solutions
- Real-time syndromic PCR tests
- Nadis^® – Patient Medical Record used in more than 200 hospitals in France for the management of HIV and hepatitis.
- MediaChek^® – Clinical Sample Collection Kits.

ABL Diagnostics, headquartered in Woippy, is a public limited company listed on compartment B of the regulated market of Euronext in Paris (Euronext: ABLD – ISIN: FR001400AHX6). These molecular biology products generate recurring revenues and cover one of the largest portfolios of applications in microbiology.

Contact
ABL Diagnostics SA
Société anonyme au capital de 1 611 465,60 euros
Headquarters : 72C route de Thionville - 57140 WOIPPY
552 064 933 R.C.S. METZ Tel : +33 (0)7 83 64 68 50
Email : info@abldiagnostics.com
https://www.abldiagnostics.com/

Dr Sayada
ABL Diagnostics SA
+33 7 83 64 68 50
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.